ONC-841

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameONC-841
Drug Alias NameAnti-SIGLEC10 antibody (OncoC4)ONC-841
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Signal transducer CD24Sialic acid-binding Ig-like lectin 10 inhibitors
TargetsSignal transducer CD24Sialic acid-binding Ig-like lectin 10
Therapy Area/IndicationsSolid tumoursAlzheimer DiseaseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAcroImmune Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Anke Immune Technology Co LtdAcroImmune GroupOncoc4 Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursAlzheimer DiseaseNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A